UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40323 RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 46-4099738 (State or ...

Exhibit 99.1 Recursion Provides Business Updates and Reports Third Quarter 2024 Financial Results • Multiple clinical trial milestones were achieved, including encouraging topline data for a Phase 2 trial in CCM, the first patient dosed for a Phase 2 trial in recurrent C. difficile infection, and IND clearance for a Phase 1/2 trial in biomarker-enriched solid tumors and lymphoma (Target RBM39), which highlight a growing number of potential clinical program catalysts • Our first neuroscience phenomap was opt ...

文章核心观点 - 尽管生物科技股票存在巨大风险,但Recursion Pharmaceuticals (RXRX)作为一家生物科技公司,却拥有颠覆性和潜在的百倍收益的可能[1][2] - Recursion Pharmaceuticals的核心在于其自主研发的药物开发软件平台Recursion OS,该平台可以利用人工智能和高性能计算来模拟药物分子的创造和作用,从而大幅降低药物研发成本和时间[6][7][8] - 这种AI驱动的药物开发方式是未来的趋势,预计未来10年内将以21.5%的年复合增长率快速发展[11] 根据目录分别总结 公司概况 - Recursion Pharmaceuticals是一家市值20亿美元的生物科技公司,目前收入较少,亏损较大[3] - 公司目前有6个药物管线,其中最先进的REC-994已经完成了II期临床试验,并获得了安全性和耐受性的确认[4][5] 核心技术 - Recursion OS是公司的核心利润来源,该平台利用人工智能和大数据技术,可以模拟药物分子的创造和作用,大幅降低药物研发成本和时间[6][8] - 该技术可以帮助制药公司筛选出最有前景的药物候选,避免无谓的临床试验投入[10] 行业前景 - 传统药物研发成本高昂,平均每个新药需要10-20亿美元的投入,且9成药物在临床试验中失败[9][10] - 采用AI辅助的药物开发方式可以大幅降低成本和时间,这种技术未来10年将以21.5%的年复合增长率快速发展[11]

Recursion Pharmaceuticals (RXRX) ended the recent trading session at $6.40, demonstrating a +1.27% swing from the preceding day's closing price. The stock outpaced the S&P 500's daily gain of 0.41%. Meanwhile, the Dow gained 0.69%, and the Nasdaq, a tech-heavy index, added 0.8%.Shares of the biotechnology company have appreciated by 4.29% over the course of the past month, outperforming the Medical sector's loss of 4.61% and the S&P 500's loss of 0.97%.Investors will be eagerly watching for the performance ...

Recursion Pharmaceuticals (RXRX) ended the recent trading session at $6.68, demonstrating a -0.89% swing from the preceding day's closing price. The stock trailed the S&P 500, which registered a daily loss of 0.33%. Meanwhile, the Dow lost 0.22%, and the Nasdaq, a tech-heavy index, lost 0.56%. The biotechnology company's shares have seen an increase of 9.24% over the last month, surpassing the Medical sector's loss of 4.31% and the S&P 500's gain of 1.83%. Investors will be eagerly watching for the performa ...

This company stands to benefit from a shifting pharmaceutical industry landscape. As a biotech that's leaning heavily on artificial intelligence (AI) in every aspect of its business, Recursion Pharmaceuticals (RXRX 1.89%) is hooked into a handful of big trends that will likely define the future of its industry. There isn't any guarantee that the company will be a good investment on the force or direction of those trends alone. But there are three which are especially bullish for the stock thanks to how it's ...

Recursion Pharmaceuticals (RXRX) closed at $6.36 in the latest trading session, marking a +0.47% move from the prior day. This change outpaced the S&P 500's 0.22% gain on the day. Meanwhile, the Dow lost 0.33%, and the Nasdaq, a tech-heavy index, added 0.76%.Coming into today, shares of the biotechnology company had lost 8.13% in the past month. In that same time, the Medical sector lost 3.79%, while the S&P 500 gained 1.47%.The investment community will be closely monitoring the performance of Recursion Ph ...

Wood has a stake in this stock, but it's hardly an "all-in" bet. Artificial intelligence (AI) is changing the way we do business. Companies are racing to implement it in umpteen different ways, knowing that the most successful will reap immense financial benefits. That's why investors are also searching for the most exciting AI stocks, but picking the right one might not be easy. How about getting some inspiration from famous investors? Cathie Wood, the CEO of Ark Invest, has several AI stocks in her invest ...

This clinical-stage drugmaker's AI platform could speed up the development process, but initial results were disappointing. The artificial intelligence (AI) revolution is pushing up the overall stock market, but not every AI stock is performing well. Shares of Recursion Pharmaceuticals (RXRX 1.51%) are down by more than half from a peak they set this spring. The start-up drugmaker disappointed investors with lackluster results for its lead candidate in September. Luckily, it has a deep pipeline of less-adva ...

These two AI innovators are reshaping drug discovery and voice technology – find out why Wall Street sees major upside ahead. Artificial intelligence (AI) is poised to revolutionize the global economy. By 2030, AI could add $15.7 trillion to worldwide GDP, a 26% increase, according to a report by PwC, a leading global consulting firm. This projected growth is expected to stem from significant productivity gains and increased consumer demand. A study by the World Economic Forum, an international organization ...